Investors
2023 Annual Report and ESG Performance Report
With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.
2023 Annual Report
Investors
We announced our third quarter 2023 results on Wednesday 1 November.
Press releases
- Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
- GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise
- ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges
Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSK Global links
Visit our Global site for additional features